Sign up to save your podcasts
Or
Share 314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.
View all episodes
By STAT
4.6
300300 ratings
Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.
More shows like The Readout Loud
View all
WSJ Tech News Briefing
1,634 Listeners
WSJ What’s News
4,302 Listeners
The Daily
111,779 Listeners
KFF Health News' 'What the Health?'
469 Listeners
The Long Run with Luke Timmerman
117 Listeners
The Journal.
5,900 Listeners
Morning Brew Daily
2,924 Listeners
Tradeoffs
382 Listeners
Biotech 2050 Podcast
60 Listeners
Business Of Biotech
84 Listeners
BioCentury This Week
31 Listeners
Raising Health
141 Listeners
Biotech Hangout
9 Listeners
ACQ2 by Acquired
193 Listeners
Ground Truths
44 Listeners